Re-treatment With Immune Checkpoint Inhibitors: Utilization Analysis

Immune checkpoint inhibitors (ICIs), such as pembrolizumab and cemiplimab, are approved for various cancers. Both are typically administered for up to 2 years, with evidence supporting re-treatment upon progression. Some jurisdictions allow re-treatment for an additional year (pembrolizumab) or 96 weeks (cemiplimab); however, patients progressing after this second course present a dilemma, as clinical trials lack data on further re-treatment. This study will analyze ICI re-treatment patterns in Ontario, Alberta, and British Columbia using administrative data. The outcomes include re-treatment frequency, treatment duration, and time between initial and subsequent therapies. Data may inform economic planning in public drug programs.

Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.

The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.